Novel therapeutic agents for various diseases such as cancer and infectious diseases

We are a Taiwan biotech company, subsidiary of Optimer Pharmaceuticals, Inc. in San Diego, CA, USA. Our mission is to develop novel therapeutic agents for unmet medical needs, including diseases such as cancer and infectious diseases. Our leading compound is OBI-822, an active immunotherapy for the treatment of epithelial-derived cancers, such as breast, ovarian, lung, prostate, colon, gastric and pancreatic cancer. Our company is currently conducting a Phase II/III randomized control trial (RCT) for metastatic breast cancer for OBI-822. For this study, subjects has been actively recruited from Taiwan, Hong Kong, India, Korea and the US in over 40 sites. Our company has an excellent pipeline of active immunotherapy products developed via its proprietary OPopS' Platform. In addition to OBI-822, there is the next generation cancer vaccine, OBI-833, for epithelial cancers (other than breast and ovarian) and a cancer diagnostic kit, OBI-868. To enrich our product pipeline, we also develop anti-Globo-H monoclonal antibody OBI-888 for cancer treatment. In derma-cosmetic field, OBI is developing OBI-858, a botulinum toxin product for cosmetic use.